VERIGRAFT AB
Verigraft AB is a biotech company that generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes.... VERIGRAFT’s technology does not require immunosuppression. With this unique, patented and improved alternative to existing treatments, VERIGRAFT strives to deliver a life changing impact to patients and provide major benefits for hospitals, healthcare providers and society – globally. VERIGRAFT’s personalized tissue-engineered vein (P-TEV) has gone through preclinical development at the company. Safety data from large animals has been generated. Clinical proof-of-concept in humans exists. The product is planned to enter clinical development within 6 months.
VERIGRAFT AB
Industry:
Biotechnology Life Science Medical Medical Device
Founded:
2004-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.verigraft.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.18 M EUR
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Verigraft AB
Official Site Inspections
http://www.verigraft.com
- Host name: cpsrv24.misshosting.com
- IP address: 185.76.64.174
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
